Regimen | Patients, n (%) | |
---|---|---|
1 L therapy (n = 1003) |
2 L therapy (n = 287) | |
Chemotherapy | ||
Carboplatin-based doublet or triplet therapya | 499 (49.8) | 57 (19.9) |
Carboplatin | 3 (0.3) | 0 |
Cisplatin-based doublet or triplet therapya | 172 (17.1) | 7 (2.4) |
Docetaxel | 5 (0.5) | 17 (5.9) |
Docetaxel + nintedanib | 4 (0.4) | 16 (5.6) |
Gemcitabine | 3 (0.3) | 1 (0.3) |
Nintedanib | 0 | 1 (0.3) |
Paclitaxel | 0 | 4 (1.4) |
Pemetrexed | 9 (0.9) | 0 |
Vinorelbine | 3 (0.3) | 1 (0.3) |
Immuno-oncology therapy | ||
Atezolizumab | 0 | 32 (11.1) |
Nivolumab | 5 (0.5) | 20 (7.0) |
Pembrolizumab | 174 (17.3) | 96 (33.4) |
Targeted therapyb | ||
Afatinib | 67 (6.7) | 5 (1.7) |
Alectinib | 2 (0.2) | 2 (0.7) |
Ceritinib | 6 (0.6) | 3 (1.0) |
Crizotinib | 11 (1.1) | 4 (1.4) |
Erlotinib | 12 (1.2) | 5 (1.7) |
Gefitinib | 24 (2.4) | 3 (1.0) |
Osimertinib | 4 (0.4) | 13 (4.5) |